Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Organisation › Details

Celyad S.A. (Euronext Brussels + Paris: CYAD, Nasdaq: CYAD)

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell autologous and allogeneic platforms have the potential to treat a broad range of solid and hematologic tumors. After having demonstrated safety, its lead oncology autologous CAR-T therapy CYAD-01 (CART NKG2D) is now currently being evaluated in several Phase I clinical trials to assess the clinical activity of multiple administrations of autologous CYAD-01 cells in solid cancer (metastatic colorectal cancer) and hematological tumors (acute myeloid leukemia) with or without being concurrently administered with standard-of-care treatments (preconditioning chemotherapy). Concomitantly, Celyad is developing CYAD-101, first-in-class, investigational, non-gene edited, allogeneic (donor derived) CAR-T therapy co-expressing the CAR-T NKG2D and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule). The expression of TIM reduces signaling of the TCR complex and could therefore reduce or eliminate Graft versus Host Disease (GvHD). CYAD-101 is evaluated in a Phase I trial for the treatment of patients with mCRC. Preliminary results are expected in second half of 2019. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. *

 

Period Start 2015-05-05 renamed
  Group Celyad (Group)
  Predecessor Cardio3 BioSciences S.A. (Euronext Brussels: CARD)
Products Industry C-Cure® cell therapy
  Industry 2 C-Cathez®
Persons Person Petti, Filippo (Celyad 201904 interim CEO 201809– CFO before Wells Fargo Securities + William Blair + Webush Securities)
  Person 2 Moore, Anne (Celyad 201904– VP Corporate Strategy before Bryan, Garnier Paris + Credit Suisse + Huron Consulting)
     
Region Region Mont-Saint-Guibert
  Country Belgium
  Street 12 Rue Edouard Belin
  City 1435 Mont-Saint-Guibert
  Tel +32-10-394100
    Address record changed: 2018-07-24
     
Basic data Employees C: 51 to 100 (2015-12-31)
  Currency EUR
  Annual sales 3,115,000 (revenues, consolidated (2018) 2018-12-31)
  Profit -37,427,000 (2018-12-31)
  Cash 40,542,000 (2018-12-31)
     
    * Document for �About Section�: Celyad S.A.. (3/28/19). "Press Release: Celyad Appoints Filippo Petti as Chief Executive Officer. Dr Christian Homsy Continues as Non-executive Director and Chair of the Strategy Committee of the Board of Directors". Mont-Saint-Guibert.
     
   
Record changed: 2019-04-04

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Celyad (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top